Hackensack, New Jersey (March 20, 2024)—Today, Co-CEO Dr. Jason Auerbach announces Mark Censoprano as the new Co-Chief Executive Officer at MAX Surgical Specialty Management, effective immediately. As Co-CEO, Mark will work alongside Dr. Auerbach to lead MAX’s growth strategy and executive team.

Mark’s arrival will accelerate the already exceptional growth that MAX SSM has enjoyed since its inception.  His wealth of knowledge and proven track record of success, coupled with his leadership within two of Fortune’s Top 100 Best Companies to Work For, will undoubtedly bolster the practices’ and MAX’s already outstanding reputation. As CEO, President, and CMO/COO, Mark grew Guardian Dentistry Partners into one of the most respected organizations in the industry, with 170 locations across 11 states. Mark’s experience as CMO at Aspen Dental earlier in his career, where he led transformative brand initiatives, which contributed to the doubling of sales and earnings during his tenure.

“In the short time I have known him, Mark has already proven to be an insightful, cooperative, and motivated partner with great energy and a genuinely collaborative demeanor,” says Dr. Auerbach. “That’s what set him apart, and ultimately, that’s what I believe will complement an already amazing team at MAX and our family of practices. This is a new chapter, having Mark join MAX. I am confident that his strategic vision, leadership, and industry-specific expertise will be invaluable as we continue to grow and achieve our goals while never losing focus of what got us here in the first place: our absolute dedication to our patients, to our referring doctors, and our surgeons, the heartbeat of our organization.”

Together with leadership from Dr. Auerbach and Mark Censoprano, MAX will continue to build upon the organization’s promise to reshape the future of oral & maxillofacial surgical care. The MAX team is excited for all that is to come under Mark’s guidance. To learn more about Mark, you can find him at https://www.linkedin.com/in/mark-censoprano/.

MAX is grateful to Interim Co-CEO Jeff Ward for his unwavering support in leading the MAX executive team while balancing the significant responsibilities associated with running MedEquity Capital. Mark’s addition to MAX will allow Jeff to refocus his efforts and contributions to MAX as Executive Chairman of the Board of Directors.



Sabrina Levine Communications

Sabrina Levine | sabrina@sabrinalevinepr.com | (917) 769-4434

Nicole Waldman | nicole@sabrinalevinepr.com | (805) 404-8152

About Mark Censoprano:

Mark Censoprano is a seasoned executive with over three decades of experience in competitive industries, including leadership roles at prestigious organizations and successful healthcare startups. Mark’s career began after completing a selective joint BS/MBA degree program at Cornell University. He then spent a significant period at S.C. Johnson & Son, a FORTUNE Top 100 Best Companies to Work For, where he honed his business discipline and achieved growth for top brands in brand management roles.

Following his tenure at S.C. Johnson & Son, Mark led businesses and launched new products at Campbell Soup Company’s Soup division, achieving several record-breaking product launches. As Senior Vice President at Darden Restaurants’ $3.3B Olive Garden concept, another FORTUNE Top 100 Best Companies to Work For, Mark delivered record-setting business results, outperforming all other brands in the casual dining category. In 2012, Mark became Chief Marketing Officer at Aspen Dental, leading various functions and spearheading a successful brand relaunch, resulting in historic sales, profits, patient counts, and employee engagement scores. After holding c-suite roles in the retail industry, Mark joined Guardian Dentistry Partners, a startup, where he played a pivotal role in growing the company, earning recognition as a top company to work for and partner with within the industry. Mark’s innovative efforts have been recognized by industry publications such as Ad Age, Brandweek, and USA Today. He has also received an Effie Award for Sustained Business Success.

About Dr. Jason Auerbach:

Dr. Jason M. Auerbach is a renowned Oral and Maxillofacial Surgeon certified by both the American Board of Oral and Maxillofacial Surgery and the National Dental Board of Anesthesiology. This dual certification – and the expertise it reflects – enables Dr. Auerbach to provide patients with the full range of oral and maxillofacial surgery services, including laser-assisted dental implant surgery, advanced bone grafting, wisdom tooth extraction, exposures of impacted canines for orthodontic patients, and more. He is also known internationally as an industry leader through his handle @bloodytoothguy (190K) on social media, where he educates rising dental stars. Dr. Auerbach founded Riverside Oral Surgery in 2007 and, in doing so, began to realize his vision of providing the optimal patient experience through clinical excellence, compassionate care, and close attention to every detail. This is now the leading full-scope oral group in New Jersey, with 9 locations and 15 surgeons. It is the official practice for the New Jersey Devils. Dr. Auerbach’s newest venture is MAX Surgical Specialty Management LLC, the leading disruptor in surgeon-led OMS platforms. MAX is changing the landscape for what was known possible to private practice owners, supporting 28 surgeons in 4 states across the Northeast.

About MAX Surgical Specialty Management:

Based in Hackensack, New Jersey, MAX Surgical Specialty Management is a management services organization that partners with premier oral and maxillofacial surgery (OMS) practices to drive and support clinical excellence and a superior patient experience with the intention of creating the ultimate surgeon-led OMS platform. Backed by MedEquity Capital, RF Investment Partners, and Kian Capital, MAX is committed to building the region’s first OMS-only specialty platform where surgeons’ autonomy, independent practice identity, and clinical excellence are organizational imperatives. MAX provides a superior platform to support strategic practice growth as well as scalable, effective, and efficient daily operations required to meet the needs of top performing OMS practices. Further information is available at www.max-ssm.com.

About MedEquity Capital:  

Headquartered in Wellesley, Massachusetts, MedEquity Capital is a healthcare private equity firm that focuses on investing in profitable healthcare services business, most often in the lower middle-market. Since its founding over 20 years ago, MedEquity has invested over $400 million of equity capital, with top decile returns for its investors. Further information is available at www.medequity.com.

About RF Investment Partners: RF Investment Partners provides capital ranging in size from $5 million to $30 million to support leading domestic, lower-middle-market companies. RF partners with family-owned and private businesses in a variety of situations, including acquisition financing, growth capital investments, recapitalizations, refinancings, and management buyouts. RF’s investment professionals have considerable experience investing across the capital structure and have the flexibility to structure deals to meet the distinct needs of each company and situation. RF invests in unitranche, second lien, and subordinated debt, alongside preferred and common equity. Further information is available at www.rf-partners.com